SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Man Ho Choi, Bong Chul Chung, Bringing GC–MS profiling of steroids into clinical applications, Mass Spectrometry Reviews, 2014, 33, 5
  2. 2
    Sohei Kanda, Norihiko Tsuchiya, Shintaro Narita, Takamitsu Inoue, Mingguo Huang, Syuji Chiba, Susumu Akihama, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Shigeru Satoh, Seiichi Saito, Chikara Ohyama, Yoichi Arai, Osamu Ogawa, Tomonori Habuchi, Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival, International Journal of Cancer, 2014, 135, 9
  3. 3
    Louis Gauthier-Landry, Alain Bélanger, Olivier Barbier, Multiple roles for udp-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution, The Journal of Steroid Biochemistry and Molecular Biology, 2014,

    CrossRef

  4. 4
    Funda Kosova, Gökhan Temeltaş, Zeki Arı, Murat Lekili, Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients, Tumor Biology, 2014, 35, 5, 4295

    CrossRef

  5. 5
    Anthony J. Usoro, Aniebietabasi S. Obot, Itemobong S. Ekaidem, Okon E. Akaiso, Alphonsus E. Udoh, O. Akinloye, Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders, Indian Journal of Clinical Biochemistry, 2014,

    CrossRef

  6. 6
    Y Cui, H Zong, H Yan, Y Zhang, The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis, Prostate Cancer and Prostatic Disease, 2014, 17, 2, 132

    CrossRef

  7. 7
    Z. Chen, S. Tao, Y. Gao, J. Zhang, Y. Hu, L. Mo, S.-T. Kim, X. Yang, A. Tan, H. Zhang, X. Qin, L. Li, Y. Wu, S. Zhang, S. L. Zheng, J. Xu, Z. Mo, J. Sun, Genome-wide association study of sex hormones, gonadotropins and sex hormone-binding protein in Chinese men, Journal of Medical Genetics, 2013, 50, 12, 794

    CrossRef

  8. 8
    Lucyna Konieczna, Tomasz Bączek, Mariusz Belka, Anna Fel, Marcin Markuszewski, Wiktoria Struck, Michał Markuszewski, Roman Kaliszan, Steroid profiles as potential biomarkers in patients with urogenital tract cancer for diagnostic investigations analyzed by liquid chromatography coupled to mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, 2013, 73, 108

    CrossRef

  9. 9
    Lokman Varisli, Ceren Gonen-Korkmaz, Hamid Muhammad Syed, Nuray Bogurcu, Bilge Debelec-Butuner, Burcu Erbaykent-Tepedelen, Kemal Sami Korkmaz, Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells, Molecular and Cellular Endocrinology, 2012, 350, 1, 107

    CrossRef

  10. 10
    A. Nahata, V. K. Dixit, Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats, Andrologia, 2012, 44,
  11. 11
    A.C. Hetzl, W.J. Fávaro, A. Billis, U. Ferreira, V.H.A. Cagnon, Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men, Microscopy Research and Technique, 2012, 75, 9
  12. 12
    P Dimitropoulou, R M Martin, E L Turner, J A Lane, R Gilbert, M Davis, J L Donovan, F C Hamdy, D E Neal, Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study, British Journal of Cancer, 2011, 104, 5, 875

    CrossRef

  13. 13
    Hamed Ahmadi, Farzad Allameh, Nima Baradaran, Laleh Montaser-Kouhsari, Shahrzad Bazargan-Hejazi, Sepehr Salem, Abdolrasoul Mehrsai, Gholamreza Pourmand, Circulating Sex Hormones Play No Role in the Association between Sexual Activity and the Risk of Prostate Cancer, The Journal of Sexual Medicine, 2011, 8, 3
  14. 14
    Yousra Souiden, Manel Mahdouani, Kamel Chaieb, Rafik Elkamel, Kacem Mahdouani, CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population, Cancer Epidemiology, 2011, 35, 5, 480

    CrossRef

  15. 15
    John M. Fitzpatrick, Joaquim Bellmunt, Robert Dreicer, Neil E. Fleshner, Christopher J. Logothetis, Judd W. Moul, Bertrand Tombal, Alexandre Zlotta, Maximizing outcomes in genitourinary cancers across the treatment continuum, BJU International, 2011, 107,
  16. 16
    Piotr Bryniarski, Andrzej Paradysz, Mieczyslaw Fryczkowski, PSA mass as a marker of prostate cancer progression after radical prostatectomy, Medical Science Monitor, 2011, 17, 2, CR104

    CrossRef

  17. 17
    Barbara K. Dunn, Ellen S. Richmond, Lori M. Minasian, Anne M. Ryan, Leslie G. Ford, A Nutrient Approach to Prostate Cancer Prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT), Nutrition and Cancer, 2010, 62, 7, 896

    CrossRef

  18. 18
    Jieying Jiang, Nelson L.S. Tang, C. Ohlsson, Anna L. Eriksson, Liesbeth Vandenput, Frank W.K. Chan, Jasmine K.L. Ching, Anthony Kwok, Eric Orwoll, Timothy C.Y. Kwok, Jean Woo, Ping Chung Leung, Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men, Clinica Chimica Acta, 2010, 411, 1-2, 53

    CrossRef

  19. 19
    Ana M. G. Custodio, Fernanda C. A. Santos, Silvana G. P. Campos, Patricia Simone Leite Vilamaior, Sérgio M. Oliveira, Rejane M. Góes, Sebastião R. Taboga, Disorders related with ageing in the gerbil female prostate (Skene’s paraurethral glands), International Journal of Experimental Pathology, 2010, 91, 2
  20. 20
    Uzair B Chaudhary, Jeffrey S Turner, Finasteride, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 7, 873

    CrossRef

  21. 21
    Sarah L Hulin-Curtis, Dominique Petit, W Douglas Figg, Ann W Hsing, Juergen KV Reichardt, Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer, Future Oncology, 2010, 6, 12, 1897

    CrossRef

  22. 22
    Bo Sung Shin, Eu Chang Hwang, Chang Min Im, Sun-ouck Kim, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Kwangsung Park, Soo Bang Ryu, Is a Decreased Serum Testosterone Level a Risk Factor for Prostate Cancer? A Cohort Study of Korean Men, Korean Journal of Urology, 2010, 51, 12, 819

    CrossRef

  23. 23
    Maria D. Jackson, Norma D. McFarlane-Anderson, Garfield A. Simon, Franklyn I. Bennett, Susan P. Walker, Urinary phytoestrogens and risk of prostate cancer in Jamaican men, Cancer Causes & Control, 2010, 21, 12, 2249

    CrossRef

  24. 24
    Takashi Imamoto, Hiroyoshi Suzuki, Takanobu Utsumi, Takumi Endo, Makoto Takano, Masashi Yano, Koji Kawamura, Naoto Kamiya, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa, Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels, Future Oncology, 2009, 5, 7, 1005

    CrossRef

  25. 25
    Joep G.H. Van Roermund, Dieuwertje E.G. Kok, Mark F. Wildhagen, Lambertus A. Kiemeney, Femke Struik, Sarah Sloot, Inge M. Van Oort, Christina A. Hulsbergen-van de Kaa, Geert J.L.H. Van Leenders, Chris H. Bangma, J. Alfred Witjes, Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy, BJU International, 2009, 104, 3
  26. 26
    Carol H. Christensen, Elizabeth A. Platz, Gabriella Andreotti, Aaron Blair, Jane A. Hoppin, Stella Koutros, Charles F. Lynch, Dale P. Sandler, Michael C.R. Alavanja, Coumaphos Exposure and Incident Cancer among Male Participants in the Agricultural Health Study (AHS), Environmental Health Perspectives, 2009,

    CrossRef

  27. 27
    Reiko Suzuki, Naomi E. Allen, Paul N. Appleby, Timothy J. Key, Laure Dossus, Anne Tjønneland, Nina Føns Johnsen, Kim Overvad, Carlotta Sacerdote, Domenico Palli, Vittorio Krogh, Rosario Tumino, Sabine Rohrmann, Jakob Linseisen, Heiner Boeing, Antonia Trichopoulou, Georgios Makrygiannis, Gesthimani Misirli, H. Bas Bueno-de-Mesquita, Anne M. May, María José Tormo Díaz, Maria-José Sánchez, Aurelio Barricarte Gurrea, Laudina Rodríguez Suárez, Genevieve Buckland, Nerea Larrañaga, Sheila Bingham, Kay-Tee Khaw, Sabina Rinaldi, Nadia Slimani, Mazda Jenab, Elio Riboli, Rudolf Kaaks, Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC), Cancer Causes & Control, 2009, 20, 6, 811

    CrossRef

  28. 28
    Lara S. Corradi, Silvana G. P. Campos, Fernanda C. A. Santos, Patricia S. L. Vilamaior, Rejane M. Góes, Sebastião R. Taboga, Long-term inhibition of 5-alpha reductase and aromatase changes the cellular and extracellular compartments in gerbil ventral prostate at different postnatal ages, International Journal of Experimental Pathology, 2009, 90, 1
  29. You have free access to this content29
    Li Yang, Nilesh W. Gaikwad, Jane Meza, Ercole L. Cavalieri, Paola Muti, Bruce Trock, Eleanor G. Rogan, Novel biomarkers for risk of prostate cancer: Results from a case–control study, The Prostate, 2009, 69, 1
  30. You have free access to this content30
    Takayuki Kurosaki, Motofumi Suzuki, Yutaka Enomoto, Tomio Arai, Motoji Sawabe, Takayuki Hosoi, Yukio Homma, Tadaichi Kitamura, Polymorphism of cytochrome P450 2B6 and prostate cancer risk: A significant association in a Japanese population, International Journal of Urology, 2009, 16, 4
  31. 31
    Leonard S. Marks, Re: Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies, European Urology, 2009, 55, 3, 750

    CrossRef

  32. 32
    Young-Kyo Seo, Bing Zhu, Tae-Il Jeon, Timothy F. Osborne, Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin, Experimental Cell Research, 2009, 315, 18, 3133

    CrossRef

  33. 33
    N. Baradaran, H. Ahmadi, S. Salem, M. Lotfi, Y. Jahani, N. Baradaran, A.R. Mehrsai, G. Pourmand, The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones, The Prostate, 2009, 69, 16
  34. 34
    W.J. Fávaro, C.R. Padovani, V.H.A. Cagnon, Ultrastructural and proliferative features of the ventral lobe of the prostate in non-obese diabetic mice (NOD) following androgen and estrogen replacement associated to insulin therapy, Tissue and Cell, 2009, 41, 2, 119

    CrossRef

  35. 35
    Silvana Gisele Pegorin Campos, Cristiani Zanetoni, Wellerson Rodrigo Scarano, Patrícia Simone Leite Vilamaior, Sebastião Roberto Taboga, Age-related histopathological lesions in the Mongolian gerbil ventral prostate as a good model for studies of spontaneous hormone-related disorders, International Journal of Experimental Pathology, 2008, 89, 1
  36. 36
    Sara Wirén, Pär Stattin, Androgens and prostate cancer risk, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 4, 601

    CrossRef

  37. 37
    Lisa W Chu, Juergen KV Reichardt, Ann W Hsing, Androgens and the molecular epidemiology of prostate cancer, Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 3, 261

    CrossRef

  38. 38
    Erin R. Gardner, Christoph M. Ahlers, Suneet Shukla, Tristan M. Sissung, Sandra B. Ockers, Douglas K. Price, Akinobu Hamada, Robert W. Robey, Seth M. Steinberg, Suresh V. Ambudkar, William L. Dahut, William D. Figg, Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival, BJU International, 2008, 102, 11
  39. 39
    Leonard S. Marks, Does testosterone administration affect the prostate?, Current Sexual Health Reports, 2008, 5, 4, 190

    CrossRef

  40. 40
    Jocelyn M. Weiss, Wen-Yi Huang, Sabina Rinaldi, Thomas R. Fears, Nilanjan Chatterjee, Ann W. Hsing, E. David Crawford, Gerald L. Andriole, Rudolf Kaaks, Richard B. Hayes, Endogenous sex hormones and the risk of prostate cancer: A prospective study, International Journal of Cancer, 2008, 122, 10
  41. 41
    Jenni Bernoulli, Emrah Yatkin, Arto Laakso, Mikael Anttinen, Maarten Bosland, Katherine Vega, Markku Kallajoki, Risto Santti, Liisa Pylkkänen, Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat, The Prostate, 2008, 68, 7
  42. You have free access to this content42
    Takashi Imamoto, Hiroyoshi Suzuki, Masashi Yano, Koji Kawamura, Naoto Kamiya, Kazuhiro Araki, Akira Komiya, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa, The role of testosterone in the pathogenesis of prostate cancer, International Journal of Urology, 2008, 15, 6
  43. 43
    Jong Y. Park, Jean-Paul Tanner, Thomas A. Sellers, Yifan Huang, Colleen K. Stevens, Nicole Dossett, Ravi A. Shankar, Babu Zachariah, Randy Heysek, Julio Pow-Sang, Association Between Polymorphisms in HSD3B1 and UGT2B17 and Prostate Cancer Risk, Urology, 2007, 70, 2, 374

    CrossRef

  44. 44
    Jinpei Kumagai, Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Tetsuo Ogushi, Kuniko Horie-Inoue, Yasuyoshi Ouchi, Tadaichi Kitamura, Masami Muramatsu, Bruce Blumberg, Satoshi Inoue, Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer, The Prostate, 2007, 67, 10
  45. 45
    Barbara K. Dunn, Leslie G. Ford, Hormonal interventions to prevent hormonal cancers: breast and prostate cancers, European Journal of Cancer Prevention, 2007, 16, 3, 232

    CrossRef

  46. 46
    Tanja Stocks, Annekatrin Lukanova, Sabina Rinaldi, Carine Biessy, Laure Dossus, Bernt Lindahl, Göran Hallmans, Rudolf Kaaks, Pär Stattin, Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden, International Journal of Cancer, 2007, 120, 12
  47. 47
    P. Irigaray, J.A. Newby, S. Lacomme, D. Belpomme, Overweight/obesity and cancer genesis: More than a biological link, Biomedicine & Pharmacotherapy, 2007, 61, 10, 665

    CrossRef

  48. 48
    Christine Neslund-Dudas, Cathryn H. Bock, Kristin Monaghan, Nora L. Nock, James J. Yang, Andrew Rundle, Deliang Tang, Benjamin A. Rybicki, SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness, The Prostate, 2007, 67, 15
  49. 49
    Joep G. H. van Roermund, J. Alfred Witjes, The impact of obesity on prostate cancer, World Journal of Urology, 2007, 25, 5, 491

    CrossRef

  50. 50
    Carla J. Gallagher, Fred F. Kadlubar, Joshua E. Muscat, Christine B. Ambrosone, Nicholas P. Lang, Philip Lazarus, The UGT2B17 gene deletion polymorphism and risk of prostate cancer, Cancer Detection and Prevention, 2007, 31, 4, 310

    CrossRef

  51. 51
    Manlio A Goetzl, Jeffrey M Holzbeierlein, Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice, Nature Clinical Practice Urology, 2006, 3, 8, 422

    CrossRef

  52. 52
    Clareann H. Bunker, Joseph M. Zmuda, Alan L. Patrick, Victor W. Wheeler, Joel L. Weissfeld, Lewis H. Kuller, Jane A. Cauley, High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey, Cancer Causes & Control, 2006, 17, 8, 1083

    CrossRef

  53. 53
    P.B. Gray, A. Kruger, H.W. Huisman, M.P. Wissing, H.H. Vorster, Predictors of South African male testosterone levels: the THUSA study, American Journal of Human Biology, 2006, 18, 1
  54. 54
    Chiaojung J. Tsai, Barbara A. Cohn, Piera M. Cirillo, David Feldman, Frank Z. Stanczyk, Alice S. Whittemore, Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States), Cancer Causes & Control, 2006, 17, 10, 1237

    CrossRef

  55. 55
    Tsutomu Nishiyama, Kazuya Suzuki, Kazutoshi Yamana, Etsuko Tonegawa, Koichi Wako, Kota Takahashi, Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer, Expert Review of Anticancer Therapy, 2006, 6, 2, 259

    CrossRef

  56. 56
    Sara Lindström, S. Lilly Zheng, Fredrik Wiklund, Björn-Anders Jonsson, Hans-Olov Adami, Katarina Augustsson Bälter, Anthony J. Brookes, Jielin Sun, Bao-Li Chang, Wennuan Liu, Ge Li, William B. Isaacs, Jan Adolfsson, Henrik Grönberg, Jianfeng Xu, Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway, The Prostate, 2006, 66, 16
  57. 57
    Leonard S Marks, Peter S Nelson, Testosterone supplementation and the prostate: a review of the safety issue, Current Opinion in Internal Medicine, 2006, 5, 4, 425

    CrossRef

  58. 58
    Bulent Akduman, E. David Crawford, The PCPT: New Findings, New Insights, and Clinical Implications for the Prevention of Prostate Cancer, European Urology Supplements, 2006, 5, 9, 634

    CrossRef

  59. 59
    Ilir Agalliu, Ellen A. Eisen, David Kriebel, Margaret M. Quinn, David H. Wegman, A biological approach to characterizing exposure to metalworking fluids and risk of prostate cancer (United States), Cancer Causes & Control, 2005, 16, 4, 323

    CrossRef

  60. 60
    Rumi Fujita, Jie Liu, Kuniyoshi Shimizu, Fumiko Konishi, Kiyoshi Noda, Shoichiro Kumamoto, Chie Ueda, Hisatoshi Tajiri, Shuhei Kaneko, Yoshitaro Suimi, Ryuichiro Kondo, Anti-androgenic activities of Ganoderma lucidum, Journal of Ethnopharmacology, 2005, 102, 1, 107

    CrossRef

  61. 61
    Sabine Rohrmann, Dina N. Paltoo, Elizabeth A. Platz, Sandra C. Hoffman, George W. Comstock, Kathy J. Helzlsouer, Association of Vasectomy and Prostate Cancer Among Men in a Maryland Cohort, Cancer Causes & Control, 2005, 16, 10, 1189

    CrossRef

  62. 62
    Stephen J. Freedland, Martha K. Terris, Elizabeth A. Platz, Joseph C. Presti, Body mass index as a predictor of prostate cancer: Development versus detection on biopsy, Urology, 2005, 66, 1, 108

    CrossRef

  63. 63
    Jeffrey P. Bejma, Dena Walsh, Muammer Kendirci, Wayne J. G. Hellstrom, Controversies regarding testosterone supplementation in the prostate cancer patient, Current Sexual Health Reports, 2005, 2, 1, 41

    CrossRef

  64. 64
    Stephen J. Freedland, William B. Isaacs, Explaining racial differences in prostate cancer in the United States: Sociology or biology?, The Prostate, 2005, 62, 3
  65. 65
    STEPHEN J. FREEDLAND, KELLY A. GRUBB, SINDY K. YIU, MATTHEW E. NIELSEN, LESLIE A. MANGOLD, WILLIAM B. ISAACS, JONATHAN I. EPSTEIN, ALAN W. PARTIN, OBESITY AND CAPSULAR INCISION AT THE TIME OF OPEN RETROPUBIC RADICAL PROSTATECTOMY, The Journal of Urology, 2005, 174, 5, 1798

    CrossRef

  66. 66
    Stephen J. Freedland, William J. Aronson, Obesity and prostate cancer, Urology, 2005, 65, 3, 433

    CrossRef

  67. 67
    STEPHEN J. FREEDLAND, KELLY A. GRUBB, SINDY K. YIU, ELIZABETH B. HUMPHREYS, MATTHEW E. NIELSEN, LESLIE A. MANGOLD, WILLIAM B. ISAACS, ALAN W. PARTIN, OBESITY AND RISK OF BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY AT A TERTIARY CARE REFERRAL CENTER, The Journal of Urology, 2005, 174, 3, 919

    CrossRef

  68. 68
    Stephen J. Freedland, Michael C. Haffner, Patricia K. Landis, Christopher S. Saigal, H. Ballentine Carter, Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy, Urology, 2005, 65, 6, 1131

    CrossRef

  69. 69
    Yan-Ru Lou, Teemu Murtola, Pentti Tuohimaa, Regulation of aromatase and 5α-reductase by 25-hydroxyvitamin D3, 1α,25-dihydroxyvitamin D3, dexamethasone and progesterone in prostate cancer cells, The Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 1-3, 151

    CrossRef

  70. 70
    Rudolf Kaaks, Anne McTiernan, Cancer Prevention and Management through Exercise and Weight Control, 2005,

    CrossRef

  71. 71
    Pär Stattin, Circulating testosterone and prostate cancer. A brief review, Andrologie, 2004, 14, 4, 375

    CrossRef

  72. 72
    G. Kesava Reddy, Oliver Sartor, Finasteride, a Selective 5-Alpha-Reductase Inhibitor, in the Prevention and Treatment of Human Prostate Cancer, Clinical Prostate Cancer, 2004, 2, 4, 206

    CrossRef

  73. 73
    Pär Stattin, Sonja Lumme, Leena Tenkanen, Henrik Alfthan, Egil Jellum, Göran Hallmans, Steinar Thoresen, Timo Hakulinen, Tapio Luostarinen, Matti Lehtinen, Joakim Dillner, Ulf-Håkan Stenman, Matti Hakama, High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study, International Journal of Cancer, 2004, 108, 3
  74. 74
    Eugenia E. Calle, Rudolf Kaaks, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nature Reviews Cancer, 2004, 4, 8, 579

    CrossRef

  75. 75
    Murali Gopalakrishnan, Char-Chang Shieh, Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders, Expert Opinion on Therapeutic Targets, 2004, 8, 5, 437

    CrossRef

  76. 76
    Pär Stattin, Testostérone circulante et cancer de la prostate. Revue de données récentes, Andrologie, 2004, 14, 4, 381

    CrossRef

  77. 77
    Ian M Thompson, Joseph A Basler, Robin Leach, Dean Troyer, Eric Klein, Otis Brawley, Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer, Urologic Oncology: Seminars and Original Investigations, 2003, 21, 1, 73

    CrossRef

  78. 78
    Yuichiro Tanaka, Masahiro Sasaki, Masanori Kaneuchi, Hiroaki Shiina, Mikio Igawa, Rajvir Dahiya, Polymorphisms of estrogen receptor alpha in prostate cancer, Molecular Carcinogenesis, 2003, 37, 4
  79. 79
    Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Gary J. Miller, Leslie G. Ford, Michael M. Lieber, R. Duane Cespedes, James N. Atkins, Scott M. Lippman, Susie M. Carlin, Anne Ryan, Connie M. Szczepanek, John J. Crowley, Charles A. Coltman, The Influence of Finasteride on the Development of Prostate Cancer, New England Journal of Medicine, 2003, 349, 3, 215

    CrossRef

  80. 80
    Y.C. Wong, X.H. Wang, M.T. Ling, International Review of Cytology Volume 227, 2003,

    CrossRef